Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.
Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 10, 31 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020, provides an overview of the Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline landscape.
Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.
REPORT HIGHLIGHTS
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 10, 31 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.
Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The pipeline guide provides a snapshot of the global therapeutic landscape of Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acute Renal Failure (ARF) (Acute Kidney Injury) (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
Appendix
Acute Renal Failure (ARF) (Acute Kidney Injury) - Overview
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Development
Acute Renal Failure (ARF) (Acute Kidney Injury) - Therapeutics Assessment
Acute Renal Failure (ARF) (Acute Kidney Injury) - Companies Involved in Therapeutics Development
Acute Renal Failure (ARF) (Acute Kidney Injury) - Drug Profiles
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products
Acute Renal Failure (ARF) (Acute Kidney Injury) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2020
Number of Products under Development for Acute Renal Failure (ARF) (Acute Kidney Injury), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by A1M Pharma AB, H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline by Alloksys Life Sciences BV, H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Dormant Projects, H1 2020 (Contd..1), H1 2020
Acute Renal Failure (ARF) (Acute Kidney Injury) - Discontinued Products, H1 2020
Acute kidney failure occurs when kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure and kidney diseases. Treatment includes antibiotics and diuretics.
Acute Renal Failure (ARF) (Acute Kidney Injury) pipeline therapeutics constitutes close to 49 molecules. Out of which approximately 45 molecules are developed by Companies and remaining by the Universities/Institutes.
Global Markets Direct's latest report, 'Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2019', provides comprehensive information on the therapeutics under development for Acute Renal Failure (ARF) (Acute Kidney Injury) - Pipeline Review, H1 2019 , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
